Trial reportPloS one2011
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
Trial report in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.Brain : a journal of neurology · 2025Review
- Icariin ameliorates the cuprizone-induced demyelination associated with antioxidation and anti-inflammation.Inflammopharmacology · 2024Article
- Bayesian approach for predicting responses to therapy from high-dimensional time-course gene expression profiles.BMC bioinformatics · 2021Article
- Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.EBioMedicine · 2019Article
- Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles.Scientific reports · 2019Article
- Review
- Pharmacogenomics of Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2019Review
- Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.JCI insight · 2018Article
- Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Association of CD58 Polymorphism with Multiple Sclerosis and Response to Interferon ß Therapy in A Subset of Iranian Population.Cell journal · 2015Article
- Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.PloS one · 2015Article
- Biomarkers of therapeutic response in multiple sclerosis: current status.Molecular diagnosis & therapy · 2014Review
- How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2014Review
- Immunomodulatory activity of interferon-beta.Annals of clinical and translational neurology · 2014Review
- Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology.Frontiers in immunology · 2013Review
- Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.JAMA neurology · 2013Article
- An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.Science translational medicine · 2012Article
- Janus-like effects of type I interferon in autoimmune diseases.Immunological reviews · 2012Review
- Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInterferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action are incompletely understood, individual treatment response varies, and biological markers predicting response to treatment have yet to be identified.
methodsThe relationship between the molecular response to IFNβ and treatment response was determined in 85 patients using a longitudinal design in which treatment effect was categorized by brain magnetic resonance imaging as good (n = 70) or poor response (n = 15). Molecular response was quantified using a customized cDNA macroarray assay for 166 IFN-regulated genes (IRGs).
resultsThe molecular response to IFNβ differed significantly between patients in the pattern and number of regulated genes. The molecular response was strikingly stable for individuals for as long as 24 months, however, suggesting an individual 'IFN response fingerprint'. Unexpectedly, patients with poor response showed an exaggerated molecular response. IRG induction ratios demonstrated an exaggerated molecular response at both the first and 6-month IFNβ injections.
conclusionMS patients exhibit individually unique but temporally stable biological responses to IFNβ. Poor treatment response is not explained by the duration of biological effects or the specific genes induced. Rather, individuals with poor treatment response have a generally exaggerated biological response to type 1 IFN injections. We hypothesize that the molecular response to type I IFN identifies a pathogenetically distinct subset of MS patients whose disease is driven in part by innate immunity. The findings suggest a strategy for biologically based, rational use of IFNβ for individual MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.